Oxford Gene Technology Ltd has appointed Bob Holland, an expert in biomarker-driven drug development, as chief medical officer. Mr Holland was formerly vice president and head of personalised healthcare and biomarkers at AstraZeneca Plc. In this position, he helped build a pipeline of 14 drug programmes that were matched with potential companion diagnostic tests. At OGT, he will apply his expertise to cancer profiling and biomarker development.
Oxford Gene Technology announced the appointment on 21 October 2013.
Copyright 2013 Evernow Publishing Ltd